The Hodgkin's Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the label expansion of Adcetris and the approval of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).

CONTENT OVERVIEW

From disease basics to insightful analysis of market dynamics, Hodgkin’s lymphoma | Disease Landscape & Forecast | US and EU5 provides comprehensive disease coverage addressing critical aspects of the Hodgkin’s lymphoma pharmaceutical market based on primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug-treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a topline review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.

WHAT YOU WILL LEARN IN THIS CONTENT

  • How large is the drug-treatable Hodgkin’s lymphoma population and how will drug-treatment rates change over time?
  • What is the current state of treatment in Hodgkin’s lymphoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in Hodgkin’s lymphoma? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?

KEY DRUGS COVERED

Adcetris, Opdivo, Keytruda, Farydak, Rituxan/MabThera

KEY COMPANIES MENTIONED

  • Seattle Genetics
  • Takeda
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis
  • Roche/Genentech

Table of contents

  • Hodgkin's Lymphoma - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
        • Hodgkin's Lymphoma Market Parameters and Forecast
        • Hodgkin's Lymphoma SWOT Analysis
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Expert Insight
        • Market Overview
        • Hodgkin's Lymphoma Market Landscape
      • Drivers and Constraints
        • What Factors Are Driving the Market for Hodgkin's Lymphoma?
        • What Factors Are Constraining the Market for Hodgkin's Lymphoma?
        • Market Share of Hodgkin's Lymphoma Drug Classes, 2015
        • Market Share of Hodgkin's Lymphoma Drug Classes, 2025
      • Drug-Class-Specific Trends
        • Immune Checkpoint Inhibitors
        • Monoclonal Antibodies/Antibody-Drug Conjugates
        • Hodgkin's Lymphoma Sales of Monoclonal Antibodies/Antibody-Drug Conjugates, 2015 and 2025
    • Forecast
      • Forecast Sales of Key Therapies in Hodgkin's Lymphoma
    • Etiology and Pathophysiology
      • Etiology
        • Reed-Sternberg Cells and Normal Lymphocytes
      • Pathophysiology
        • Normal B-cell Development and Cellular Origin of B-Cell Malignancies
      • Classification of Hodgkin's Lymphoma
        • WHO Classification of Hodgkin's Lymphoma
      • Risk Assessment and Staging of Hodgkin's Lymphoma
        • Hodgkin's Lymphoma Staging
        • Hodgkin's Lymphoma Staging
        • Hodgkin's Lymphoma Grouping for Treatment
      • Key Pathways and Drug Targets
      • Epidemiology Overview
        • Introduction
          • Key Findings
          • Expert Insights
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Hodgkin's Lymphoma over the Next 10 Years
          • Incidence of Hodgkin's Lymphoma per 100,000 per Year Among People of All Ages in 2015 and 2025
          • Analysis of the Incident Cases of Hodgkin's Lymphoma in 2015 by Subtype
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Incidence of Hodgkin’s Lymphoma
          • Diagnosed Incident Cases of Hodgkin's Lymphoma in the Major Pharmaceutical Markets, 2015-2025
          • Disease Definition
          • Methods
          • Sources Used for Stage Distribution of Hodgkin's Lymphoma
          • Diagnosed Incident Cases of Classical Hodgkin's Lymphoma in the Major Pharmaceutical Markets, by Stage, 2015-2025
          • Diagnosed Incident Cases of Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in the Major Pharmaceutical Markets, by Stage, 2015-2025
          • Number of Diagnosed Incident Cases of Hodgkin's Lymphoma, by Subpopulation and Stage, in the Major Pharmaceutical Markets, 2015
          • Disease Definition
          • Methods
          • Sources Used for Histological Subtype of Classical Hodgkin's Lymphoma
          • Diagnosed Incident Cases of Classical Hodgkin's Lymphoma in the Major Pharmaceutical Markets, by Histology, 2015-2025
          • Hodgkin's Lymphoma Patient Flow
          • Classical Hodgkin's Lymphoma
          • Number of Drug-Treatable Cases of Classical Hodgkin's Lymphoma, by Line, 2015-2025
          • Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
          • Number of Drug-Treatable Cases of Nodular Lymphocyte-Predominant Hodgkin's Lymphoma, by Line, 2015-2025
          • Sources Used for Drug-Treatable Populations of Hodgkin's Lymphoma
          • Number of Drug-Treated Cases of Classical Hodgkin's Lymphoma
          • Number of Drug-Treated Cases of Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
      • Current Treatment Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Treatment Overview
        • Diagnosis
          • Diagnostic Work-Up for Hodgkin's Lymphoma
          • Treatment Providers and Referral Patterns
          • Expert Insight on Diagnosis of Hodgkin's Lymphoma
        • Treatment Goals
          • Key End Points Used in Clinical Trials for Hodgkin's Lymphoma
          • Key Physician Insights on Clinical End Points
          • Expert Insight on Clinical End Points
        • Key Current Therapies
          • Overview
          • Mechanism of Action of Key Current Drugs or Drug Classes Used for Hodgkin's Lymphoma
          • Current Treatments Used for Hodgkin's Lymphoma
          • Radiation Techniques Used in Hodgkin's Lymphoma Treatment
          • Market Events Impacting the Use of Key Current Therapies in Hodgkin's Lymphoma
          • Clinical Analysis of ABVD for the Treatment of Hodgkin's Lymphoma
          • Advantages and Disadvantages of ABVD
          • Expert Insight on ABVD
          • Clinical Analysis of (esc)BEACOPP for the Treatment of Hodgkin's Lymphoma
          • Advantages and Disadvantages of BEACOPP
          • Expert Insight on BEACOPP
          • Clinical Analysis of Adcetris for the Treatment of Hodgkin's Lymphoma
          • Advantages and Disadvantages of Adcetris
          • Ongoing Clinical Development
          • Select Phase II and III Trials Investigating Adcetris in the Treatment of Hodgkin's Lymphoma
          • Expert Insight on Adcetris
          • Clinical Analysis of Rituxan/MabThera for the Treatment of Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
          • Advantages and Disadvantages of Rituxan/MabThera
          • Expert Insight on Rituxan/MabThera
        • Medical Practice
          • Drug-Treatable Population
          • Hodgkin's Lymphoma Treatment Guidelines, by Market
          • United States and Europe
          • Treatment Decision Tree for Hodgkin's Lymphoma: United States
          • Treatment Decision Tree for Hodgkin's Lymphoma: Europe
      • Unmet Need Overview
        • Introduction
          • Key Findings
          • Expert Insight
        • Attainment of Unmet Needs
          • Current Attainment of Unmet Needs in Hodgkin's Lymphoma
          • Future Attainment of Unmet Needs in Hodgkin's Lymphoma
          • Top Unmet Needs in Hodgkin's Lymphoma—Current and Future Attainment
          • Expert Insight on Hodgkin's Lymphoma Unmet Needs
      • Emerging Therapies Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Pipeline Overview
          • Pipeline Trends for Hodgkin's Lymphoma
        • Late-Phase Pipeline Analysis
          • Notable Developments in the Late-Phase Pipeline for Hodgkin's Lymphoma
          • Therapies in Late-Phase Development for Hodgkin's Lymphoma
          • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Hodgkin's Lymphoma
          • Emerging Therapies with Sales Potential in Hodgkin's Lymphoma: Population Positioning
        • Orphan Drug Designation
          • Expanded Market Exclusivity
          • Tax Credits
          • Support During the Drug Approval Process
          • Grants
          • Market Exclusivity
          • Fee Reductions
        • Key Emerging Therapies
          • Select Clinical Trial Results for Opdivo for the Treatment of Hodgkin's Lymphoma
          • Opdivo Clinical Development
          • Expert Insight
          • Expert Insight on Opdivo
          • Expectations for Launch and Sales Opportunity of Opdivo in Hodgkin's Lymphoma
          • Select Clinical Trial Results for Keytruda for the Treatment of Hodgkin's Lymphoma
          • Keytruda Clinical Development
          • Expert Insight
          • Expert Insight on Keytruda
          • Expectations for Launch and Sales Opportunity of Keytruda in Hodgkin's Lymphoma
          • Select Clinical Trial Results for Farydak for the Treatment of Hodgkin's Lymphoma
          • Farydak Clinical Development
          • Expert Insight
          • Expert Insight on Farydak
          • Expectations for Launch and Sales Opportunity of Farydak in Hodgkin's Lymphoma
        • Early-Phase Pipeline Analysis
          • Notable Developments in the Early-Phase Pipeline for Hodgkin's Lymphoma
          • Select Early-Phase Compounds in Development for Hodgkin's Lymphoma
      • Access and Reimbursement Overview
        • Region-Specific Reimbursement Practices
          • U.S. Reimbursement Dynamics
            • Reimbursement Dynamics in Hodgkin's Lymphoma in the United States: Current and Future
            • Current Commercial MCO Coverage in the United States
            • Commercial MCO Coverage in Next 12 Months in the United States
        • Methodology
          • Appendix
            • Brands, Marketers, and Generic Availability of Key Therapies for Hodgkin's Lymphoma, by Market
            • Experts Interviewed
            • Hodgkin's Lymphoma Bibliography
            • Key Abbreviations Related to Hodgkin's Lymphoma

        Author(s): Dana Gheorghe

        Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.


        Related Reports

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

        The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

        View Details

        Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

        The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-y...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

        In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

        In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

        View Details